Published study shows long-term benefits of NeuroPace Inc RNS System in drug-resistant epilepsy

Published study shows long-term benefits of NeuroPace Inc RNS System in drug-resistant epilepsy
NeuroPace Inc RNS study outcomes

NeuroPace Inc announced that the RNS System Post-Approval Study, now published in the Green Journal, reveals sustained long-term outcomes for patients with drug-resistant focal epilepsy.

The release of these findings in a leading medical journal marks a significant development for the treatment of epilepsy, as the RNS System continues to demonstrate safety and efficacy in real-world clinical settings. Interested readers can access the full study results and safety information through the links provided by the company.

Previous data from NeuroPace indicated that patients with multiple medication failures saw less than five percent seizure reduction, prompting consideration of device-based alternatives such as the RNS System. In a separate three-year post-approval study published in Neurology, the company reported that the RNS System delivered meaningful outcomes for patients with refractory epilepsy. The latest publication builds on this body of clinical evidence for the device.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.